Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Avantor (AVTR)

Avantor names Ludovic Brellier EVP, Bioscience & Medtech Products and Chief Transformation Officer

Neutral Impact 4 of 5 leadership Written later

Avantor said Ludovic Brellier, formerly President of Cytiva's Hardware Solutions business at Danaher, will join as Executive Vice President, Bioscience & Medtech Products (BMP) and Chief Transformation Officer effective May 1, 2026. He will lead the BMP business and the Revival Management Office, which drives transformation initiatives across the enterprise. The filing also says current BMP segment head Benoit Gourdier is moving to a segment integration role and is expected to leave no later than December 31, 2026.

Key points

  • Ludovic Brellier starts May 1, 2026 as EVP, BMP and Chief Transformation Officer
  • Brellier will lead the Revival Management Office, overseeing enterprise transformation initiatives
  • Benoit Gourdier moves to a segment integration role and is expected to depart by December 31, 2026
  • The announcement was made in a press release dated April 23, 2026

The filing

CompanyAvantor (AVTR)
Form8-K, current report
Filed with the SECApr 23, 2026, 5:07 PM ET
Accession number0001628280-26-026905

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 12:56 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 23, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.